Prostate cancer mortality in Taiwanese men: Increasing age-standardized trend in general population and increased risk in diabetic men

Annals of Medicine

Volumn 43, Issue 2, 2011, Pages 142-150

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Diabetes; mortality; mortality rate ratio; prostate cancer; underlying cause of death

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CALCULATION; CANCER MORTALITY; CLINICAL EVALUATION; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK; TAIWAN;

ADULT; AGE FACTORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; TAIWAN;

EID: 79951565391     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.530683     Document Type: Article

References (36)

1. Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J. Changing trends of prostate cancer in Asia. Aging Male. 2004;7:120-32. (Pubitemid 39272935)
2. Chang CK, Yu HJ, Chan KW, Lai MK. Secular trend and age-period-cohort analysis of prostate cancer mortality in Taiwan. J Urol. 1997;158:1845-8.
3. Colli JL, Amling CL. Exploring causes for declining prostate cancer mortality rates in the United States. Urol Oncol. 2008;26:627-33.
4. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47: 1071-8. (Pubitemid 38918167)
5. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2056-62. (Pubitemid 44877026)
6. Ragozzino M, Melton LJ III, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis. 1982;35:13-19. (Pubitemid 12213476)
7. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360-5. (Pubitemid 27418027)
8. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer. 2002;102:258-61. (Pubitemid 35222294)
9. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol. 2009;169: 937-45.
10. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer. 2009;124:1398-403.
11. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol. 2008;168:925-31.
12. Pierce BL, Plymate S, Ostrander EA, Stanford JL. Diabetes mellitus and prostate cancer risk. Prostate. 2008;68: 1126-32. (Pubitemid 351875184)
13. Darbinian JA, Ferrara AM, Van Den Eeden SK, Quesenberry CP Jr, Fireman B, Habel LA. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17:628-35. (Pubitemid 351469213)
14. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005;161: 147-52. (Pubitemid 40096789)
15. Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, et al.; Prostate, Lung, Colorectal, and Ovarian Trial Project Team. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008;19: 1267-76.
16. Mishina T, Watanabe H, Araki H, Nakao M. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate. 1985;6:423-36. (Pubitemid 15026618)
17. Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, Nagai M, et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control. 2010;21:1025-32.
18. Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, et al. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology. 2004;63:253-8. (Pubitemid 38234413)
19. Hsing AW, Chua S Jr, Gao YT, Gentzschein E, Chang L, Deng J, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst. 2001;93:783-9. (Pubitemid 32514802)
20. Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care. 2004;27:1605-9.
21. Tseng CH. Parental diabetes in Taiwanese diabetic women with and without previous gestational diabetes. Eur J Clin Invest. 2008;38:555-61. (Pubitemid 352019136)
22. Tseng CH, Tseng CP, Chong CK, Huang TP, Song YM, Chou CW, et al. Increasing incidence of diagnosed type 2 diabetes in Taiwan: analysis of data from a national cohort. Diabetologia. 2006;49:1755-60.
23. Stein KB, Snyder CF, Barone BB, Yeh HC, Peairs KS, Derr RL, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci. 2010;55: 1839-51.
24. Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E. Hormonal profi le of diabetic men and the potential link to prostate cancer. Cancer Causes Control. 2008;19:703-10.
25. Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86: s843-57.
26. Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T, et al. Serum prostate-specifi c antigen levels in men with type 2 diabetes. Diabetes Care. 2008;31:930-1.
27. Werny DM, Saraiya M, Gregg EW. Prostate-specifi c antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol. 2006;164:978-83. (Pubitemid 44729839)
28. Segars LW, Lea AR. Assessing prescriptions for statins in ambulatory diabetic patients in the United States: a national, cross-sectional study. Clin Ther. 2008;30:2159-66.
29. Winkelmayer WC, Asslaber M, Bucsics A, Burkhardt T, Schautzer A, Wieninger P, et al.; Pharmacoeconomics Advisory Council of the Austrian Sickness Funds. Impact of reimbursement changes on statin use among patients with diabetes in Austria. Wien Klin Wochenschr. 2010;122: 89-94.
30. Teeling M, Bennett K, Feely J. The infl uence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol. 2005;59:227-32. (Pubitemid 40208860)
31. Chiang CW, Chiu HF, Chen CY, Wu HL, Yang CY. Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf. 2008;17:62-9.
32. Weinstein SJ, Mackrain K, Stolzenberg-Solomon RZ, Selhub J, Virtamo J, Albanes D. Serum creatinine and prostate cancer risk in a prospective study. Cancer Epidemiol Biomarkers Prev. 2009;18:2643-9.
33. Williams ME. Diabetic CKD/ESRD 2010: a progress report? Semin Dial. 2010;23:129-33.
34. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620-5.
35. García-Rodríguez LA, Huerta-Alvarez C. Reduced risk of colo-rectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinfl ammatory drugs. Epidemiology. 2001;12: 88-93. (Pubitemid 32006467)
36. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254-8. (Pubitemid 44106500)